Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BINDLEY-WESTERN DOES $481 MIL. SALES IN 1983

Executive Summary

BINDLEY-WESTERN DOES $481 MIL. SALES IN 1983, up 11% from $433 mil. in 1982, the company reported in an interim year-end statement released Feb. 27. The chain whslr. said profit gains outpaced sales despite substantial inventory purchases at the end of 1983 and an unfavorable comparison to a reduced tax rate in 1982. Chairman William Bindley pointed out "that due to substantial investment tax credits in December, 1982, the company's fourth quarter 1982 effective tax rate was 31% compared to 47% in the 1983 quarter." Inventory purchases at the end of the year "had the effect of reducing 1983 fourth quarter income by 8› per share" or approximately $255,000. Bindley maintained that "the additional gross profit to be realized in 1984 from the December purchases would more than off-set the LIFO valuation impact on 1983 income." Bindley said that "aggressive sales efforts are producing better than anticipated results." The firm says "two new major customers" are beginning to use the whslr.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel